Abbott's hep C combo aces latest test

Abbott Laboratories ($ABT) made a late entry into the red-hot race to develop an interferon-free approach to hepatitis C. But after playing catch-up with the likes of Gilead ($GILD), it's now aiming for the inside track. Report